Aim: Alcoholic liver disease (ALD) is the most common liver disease in the Western World. Liver transplantation (LT) is the treatment for end-stage ALD. However, many transplant centers are still reluctant to transplant these patients because of the risk of alcohol relapse, recurrence of the primary liver disease and associated post-transplant complications. We examined survival rate, prevalence of primary liver disease recurrence, re-transplantation and post-transplant complications among transplanted patients for alcoholic cirrhosis compared with those transplanted for viral cirrhosis. Methods: data about patients transplanted for alcoholic and viral cirrhosis at the Gemelli Hospital from January 1995 to April 2016 were retrospectively collected. Survival rate was evaluated according to the Kaplan-Meier method. Recurrence was defined as histological evidence of primary liver disease. Data on the onset of complication, causes of death and graft failure after liver transplant were analyzed. Results: There was no statistically significant difference regarding survival rate between the two groups. Only patients transplanted for viral cirrhosis presented with primary liver disease recurrence. There was a higher rate of cancer development in patients transplanted for alcoholic cirrhosis. Cancer was the major cause of death in this population. Risk factors associated with the onset of cancer were a high MELD score at the transplant time and smoking after transplantation. Conclusion: ALD is a good indication for LT. Patients transplanted for alcoholic cirrhosis should receive regular cancer screening and should be advised against smoking.
INTRODUCTION
Alcohol use disorders (AUD) represents the most common cause of liver disease in the Western countries (Tilg and Day, 2007) . The development of alcoholic liver disease (ALD) is influenced by environmental and host factors other than alcohol consumption per se. The duration of alcohol abuse, the drinking pattern and the amount of alcohol consumed have been reported as the most important factors for ALD progression. Moreover, recent studies have suggested that gut flora could play an important role in the pathophysiology of alcoholic liver injury (Vassallo et al., 2015) . ALD ranges from simple steatosis (fatty liver) to steatohepatitis, cirrhosis and hepatocellular carcinoma (Tilg and Day, 2007) . Independently from the stage of disease, total alcohol abstinence represents the cornerstone of the management of ALD (Addolorato et al., 2016b) . Alcohol abstinence may reduce the disease progression; several studies indicate that a stable liver function and recovery from advanced liver failure may be achieved with alcohol abstinence in AUD patients with advanced ALD (Lucey, 2009) . At present, the psychosocial approaches combined with pharmacotherapies seem effective to help these patients to achieve and maintain alcohol abstinence (Addolorato et al., 2013a) . When liver function fails to improve with abstinence, liver transplantation (LT) is the treatment of choice for end-stage ALD (Addolorato et al., 2016a) . However, concerns persist about LT in patients with AUD, related to the risk of alcohol relapse, the consequent recurrence of liver disease, poor compliance with post-LT management by AUD patients, the presence of extra-hepatic alcohol-related disease and post-transplant complications (Vassallo et al., 2013) . AUD is still often considered a 'self-inflicted disease', and part of the society considers alcoholic individuals as patients not deserving LT (Neuberger et al., 1998) . Viral cirrhosis is the leading indication for LT in the Western World (O'Leary et al., 2008; Song et al., 2014) , with cirrhosis due to hepatitis C being the most frequent indication. Prior to the introduction of new direct-acting antiviral agents, recurrence of HCV infection after LT was present in all liver transplant recipients who demonstrated hepatitis C viremia at the time of transplantation (Gruener et al., 2004) . Progression to HCV-related cirrhosis was estimated to reach 20-30% at 5-year follow-up after LT, resulting in the need for retransplantation, worse outcomes and greater health care costs (Gruener et al., 2004) . Despite the high risk of HCV recurrence after LT prior to the introduction of these new direct-acting antiviral agents, it was rare for LT to be denied to an HCV-infected patient with end-stage liver disease on the grounds of HCV alone. In AUD patients with an adequate therapeutic approach for maintaining alcohol abstinence, it is possible to prevent relapse and alcohol-related liver damage after LT (GallegosOrozco and Charlton, 2016) . The treatment of hepatitis C virus infection has been advancing at breakneck speeds over the past few years with a very high cure rates ranging from 95-100%. Although these drugs may not be universally available in the short or medium-term, the high cure rate will radically change the need for liver transplant, with ALD becoming the leading indication for LT. For this reason, it is crucial to identify the best post-transplant management to improve the risk of post-transplant complications in this population. The aim of this study was therefore to assess survival rate, prevalence of primary liver disease recurrence, re-transplantation and post-transplant complications comparing transplanted patients for alcoholic cirrhosis with those transplanted for viral cirrhosis. Moreover, risk factors for post-transplant complications were analyzed.
MATERIALS AND METHODS
Between January 1995 and April 2015, 400 patients with liver cirrhosis underwent LT at the Liver Transplantation Center of the Gemelli Hospital, Rome (Italy). The diagnosis of cirrhosis was based on physical examination, biochemical laboratory tests and diagnostic imaging. Severity of cirrhosis was classified according to the Child-Pugh score. From 2003 the model of end-stage liver disease (MELD) score was used to determine which patients required LT and the priority to be attributed to their clinical status.
Patients
From a total of 400 consecutive transplanted patients, only patients with alcoholic or viral cirrhosis (HCV-related cirrhosis, HBV-related cirrhosis, combined hepatitis B and C related cirrhosis) were considered for the analysis.
Patients transplanted for combined alcoholic and viral cirrhosis were excluded
Patients with cholestatic (Primary Biliary Cholangitis and Primary Sclerosing Cholangitis), genetic, autoimmune liver diseases, cryptogenic cirrhosis, and hepatocellular carcinoma were excluded from analysis. Patients with acute liver failure (viral acute liver failure, paracetamol or mushroom poisoning, etc.) or receiving simultaneous multi-organ transplants were also excluded from the analysis. The medical records retrospectively analyzed included demographic data, Body Mass Index, Child-Pugh score, MELD, type of graft, type of immunosuppression, smoking habits and presence of diabetes. Patients were observed until their death, loss to follow-up, or graft loss. Follow-up data was collected until January 2017 for patients that were still alive. Survival of the graft was evaluated according to the Kaplan-Meier method, considering as event the death of the patients or graft loss.
Primary liver disease recurrence and re-transplantation
Data on recurrence of primary liver disease after LT and retransplantation were evaluated. All transplanted patients periodically had abdominal ultrasound scanning and blood tests. When clinically indicated, liver biopsies were performed. Histological grading according to the Ishak and Metavir classification system was used. In the group of transplanted patients for alcoholic cirrhosis, recurrence was defined as histological feature of ALD and alcohol relapse after LT. As total alcohol abstinence is required after LT (European Association for the Study of Liver, 2012; Addolorato et al., 2016a) , alcohol relapse was defined as any alcohol intake after LT. Alcohol intake was evaluated at each follow-up visit after LT using a clinical interview based on patients' self-report, Timeline Follow-Back and interview with family members. Moreover, biomarkers of alcohol consumption (γ-glutamyltransferase, mean cellular volume, aspartate aminotransferase/alanine aminotransferase >2), breath-alcohol concentration (BAC) and, starting from 2007, carbohydrate-deficient transferrin were evaluated in all patients transplanted for alcohol cirrhosis after LT. All AUDs patients received treatment including counseling and psychosocial support; baclofen was utilized as anti-craving medications from 2007 (Addolorato et al., 2007) .
In the group of patients transplanted for virus-related cirrhosis recurrence was defined as a histological evidence of viral hepatitis and positive viremia (serum HCV RNA or HBV DNA) after LT. In case of recurrence, patients were managed by the hepatologists of the Liver Disease Centre at Gemelli Hospital. Antiviral treatment was initiated with any degree of fibrosis or fibrosing cholestatic hepatitis if the clinical conditions were sufficient to undergo antiviral therapy.
Re-transplantation were performed in patients with irreversible graft failure. Patients relisted for early complication (e.g. primary non-function or hepatic artery thrombosis), developing within 30 days after LT, were excluded from the statistical analysis.
Complications after LT
The onset of complication and the causes of death or graft failure after LT were collected. Only data about acute rejection, de novo cancer (lymphoproliferative disorders and solid tumor except for non-melanoma skin tumors), hepatic artery stenosis/thrombosis, infection, metabolic (for instance, new onset of diabetes mellitus), cardiovascular and cerebrovascular disease were considered for statistical analysis. The other data about surgical complications, portal venous thrombosis, renal and hematological complications, neuropsychiatric disorder were not considered for the statistical analysis because of the poor number of events.
STATISTICAL ANALYSIS
Numerical variables were expressed as means ± SD and categorical variables were presented as values and percentages. The Pearson's Chisquare test and Fisher's exact test were used to compare categorical variables between patient groups, whereas the Student's t-test and Mann-Whitney U test were employed for continuous variables, depending on the variable distribution as assessed by the Shapiro-Wilk test. Possible associations between numerical variables were preliminary explored using Spearman's rank correlation coefficient (for couples of variables with non-normal distribution). The Kaplan-Meier method was applied to estimate survival in each patient group and distributions of survival times were compared with the Log-rank test. Logistic regression analysis with a stepwise method was performed to assess the relationship between complications after transplantation and variables of interest (for instance possible predictors), both categorical and numerical. Analyses were conducted with the MedCalc Software Version 17.4 (Ostend, Belgium) and a P-value < 0.05 was considered significant.
RESULTS
Statistical analysis included 62 patients transplanted for alcoholic cirrhosis and 92 for viral cirrhosis.
Among patients transplanted for alcoholic cirrhosis 51 (82%) were males and 11 (18%) were females, the mean age was 51.4 years; the mean Body Mass Index was 27.5 kg/m 2 , 15 (24%) patients presented with diabetes mellitus before transplantation, 12 (19%) reported alcohol relapse after transplantation, 42 (68%) used tobacco before transplantation and 18 (29%) used tobacco after transplantation.
Among patients transplanted for viral cirrhosis 68 (74%) were males, 24 (26%) were females, the mean age was 50.2 years; the mean BMI was 25.8 kg/m 2 , 17 (18%) patients presented with diabetes mellitus prior to transplantation, 35 (32%) used tobacco before transplantation and 25 (27%) used tobacco after transplantation.
The two patients group did not significantly differ in age, gender distribution and post-transplant smoking habits. Conversely, the number of patients with smoking habits before transplantation, the Body Mass Index, the MELD and Child-Pugh scores were significantly higher in the group of patients transplanted for alcoholic cirrhosis (P = 0.0003, P = 0.0142, P < 0.0001 and P = 0.02, respectively). Complete sociodemographic and clinical features of patients are as shown in Table 1 .
In the group of patients transplanted for alcoholic cirrhosis 17 (27%) patients died and nobody was lost at follow-up, while 30 (33%) died and 3 (3%) were lost at follow-up in the group of patients transplanted for viral cirrhosis. The post-transplant clinical data are reported in Table 2 . Patient survival at 50, 100, 150, 200 and 250 months from first transplantation was, respectively, 81.6%, 68.1%, 61%, 61%, 61%, for patients transplanted for alcoholic cirrhosis, whereas 69.4%, 65.6%, 62.8%, 60.1%, 53%, for those transplanted for viral cirrhosis. Patients transplanted for alcoholic cirrhosis showed a higher survival rate, although not statistically significant (Log Rank P = 0.45), in comparison with the other group of patients. KaplanMeier analysis result is shown in Fig. 1 . There was no recurrence of primary liver disease after LT among the transplanted alcoholic cirrhosis cohort compared to the 36 (39%) patients transplanted for viral cirrhosis (P < 0.0001).
In the group of patients transplanted for alcoholic cirrhosis 2 (3%) were re-transplanted, while in the group of patients with viral cirrhosis 5 (5%) were re-transplanted. The causes of re-transplantation are reported in Table 3 .
In the group of patients transplanted for alcoholic cirrhosis 11 (18%) developed acute rejection, 17 (27%) de novo cancer, 9 (15%) hepatic artery stenosis/thrombosis, 23 (37%) infection, 12 (19%) metabolic complications, 4 (6%) cardiovascular disease and 6 (10%) cerebrovascular disease. In the group of patients transplanted for viral cirrhosis 23 (25%) developed acute rejection, 11 (12%) de novo cancer, 10 (11%) hepatic artery stenosis/thrombosis, 28 (30%) infection, 12 (13%) metabolic complications, 8 (9%) cardiovascular disease and 5 (5%) cerebrovascular disease. The data about post-transplant complications are as shown in Table 4 . No significant statistically difference was found in terms of the prevalence of these complications between these two groups, except for the prevalence of de novo cancer that was higher in the group of patients transplanted for alcoholic cirrhosis than those transplanted for viral cirrhosis (P = 0.015). The types of de novo cancer in both groups are reported in Table 5 .
Among those transplanted for alcoholic cirrhosis, 7 (41%) died from de novo cancer, while 3 (10%) patients died from the same cause among the viral cirrhotic patients that were transplanted.
In the group of patients transplanted for alcoholic cirrhosis logistic regression analyses showed a negative correlation between onset of de novo cancer and MELD score (P = 0.0078) and a positive correlation with the use of tobacco after LT (P < 0.0001).
DISCUSSION
This study shows that patients who underwent LT for alcoholic cirrhosis have a higher survival rate than patients transplanted for viral cirrhosis. These findings are in line with previous studies (Mackie et al., 2001; Burra et al., 2010) , confirm and further support that LT is an appropriate indication for ALD (European Association for the Study of Liver, 2012). Nonetheless, public opinion and even some medical professionals continue to question the appropriateness of using resource for patients with ALD due to the consideration that this is a 'self-inflicted disease'. A UK study showed that general physicians believed that, given the shortage of organs, alcoholic patients should take lower priority than other candidates, even when the latter had less chance of a successful outcome from transplantation (Neuberger et al., 1998) . Other issues on the appropriateness of LT for patients with ALD are related to the risk of alcohol relapse. A previous study showed that patients transplanted for alcoholic cirrhosis have a lower prevalence of relapse and mortality rate if they are selected and managed by a team working in an Alcohol Addiction Unit within the Liver Transplantation Center (Addolorato et al., 2013b) .
In this study, primary liver disease recurrence was present only in patients transplanted for HCV-related cirrhosis. Recurrence of hepatitis C is particularly aggressive in transplanted patients, with a rapid evolution towards cirrhosis, resulting in graft loss (Rowe et al., 2008) and re-transplantation. (Firpi et al., 2009) . In this study, five patients were re-transplanted because they developed graft failure after recurrence of hepatitis C. Many physicians are concerned about retransplantation due to organ shortages, economic implications and the poorer survival rates in re-transplanted patients. Interestingly, no patients belonging to the alcoholic cirrhosis group developed recurrence, and only two were re-transplanted due to graft failure from surgical complication. The transplanted patients that reported at least an episode of alcohol relapse during follow-up were promptly treated with multimodal treatment to prevent organ damage. The absence of recurrence in this group of patients could be partially related to the prevention and prompt treatment of alcohol relapse by the team of the Alcohol Addiction Unit within the Liver Transplantation Center (Addolorato et al., 2013b) .
This study shows that patients transplanted for alcoholic cirrhosis are more prone to the onset of de novo cancer. Those patients developed de novo cancer of the upper airways and gastrointestinal tract. These data are in line with previous literature (Saigal et al., 2002; Burra et al., 2010; Nure et al., 2013) . Moreover, this study revealed that cancer is a relevant cause of death in this population. The risk factors associated with the onset of this complication are post-transplant Re-transplanted patients, n (%) 2 (3%) 5 (5%) n, number of patients. use of tobacco and a high MELD score at the time of transplantation. These risk factors act synergistically to increase post-transplantation immunosuppression. The effect is probably due to reduced immunosuppression and the activation of oncogenic viruses. However, in this study the effect of immunosuppressive drugs were not considered for the high risk of bias due to frequent change in immunosuppressive therapy during follow-up. Tobacco is used in a high percentage of patients transplanted for alcoholic cirrhosis and many patients resume smoking habits early after transplantation (Dumortier et al., 2007) and physicians do not typically encourage enough smoking cessation in this population. Use of tobacco is a well established and recognized factor for the onset of de novo cancer in transplanted patients (Dumortier et al., 2007) and is also associated with an increased mortality and morbidity from hepatic artery thrombosis and cardiovascular disease in this population (Pungpapong et al., 2002) . For these reasons, all transplanted patients should be encouraged to stop smoking (Lucey, 2014) and treatments for smoking cessation should be offered (Lee and Leggio, 2015) . Regarding alcohol relapse after transplantation, our study did not show any correlation with the onset of cancer. Similarly, a previous study indicated that alcohol relapse did not increase the risk of malignancy (Watt et al., 2009 ). In our study, this finding could be explained by the low rate (19%) of alcohol relapse compared with other studies (Mackie et al., 2001) . Furthermore, it may be critical to implement screening programs in transplanted patients, that include periodic upper digestive endoscopy, chest radiography and clinical pharyngo-laryngeal examination. Moreover, it is crucial to prevent alcohol relapse, encourage smoking cessation and avoid excessive immunosuppressive therapy. There were no differences between the two groups on the other post-transplant complications, possibly because of the small sample size. Previous studies showed an increased incidence of cardiovascular events (Burra et al., 2010) and infections in patients transplanted for alcoholic cirrhosis compared to those transplanted for other etiologies, whilst rate of rejection was lower (Farges et al., 1996) .
The main limitations of this study were small sample size, monocentric and retrospective design. Moreover, it was not possible discriminate among relapsing patients after LT those who presented only an episode of lapse.
CONCLUSION
ALD is an appropriate indication for LT. Obviously, an accurate stratification of potential candidates is needed to identify those most likely to remain abstinent after LT. Survival rate of transplanted patients for alcoholic cirrhosis are comparable with other etiologies of liver disease. Patients transplanted for alcoholic cirrhosis should be followed by specialists in AUDs working within the Liver Transplantation Center in order to help patients to prevent alcohol relapse and consequent recurrence of the primary liver disease. Patients after LT should receive regular screening for cancer, including chest radiography, upper digestive endoscopy and clinical pharyngo-laryngeal examination. Finally, they should be advised to quit smoking after LT.
